NCT04587713View on ClinicalTrials.gov

Single Dose Bioavailability and Ethnobridging PK Study in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

October 16, 2020

Primary Completion Date

December 24, 2020

Study Completion Date

December 27, 2020

Conditions
Intestinal DisorderBowel Diseases, Inflammatory
Interventions
DRUG

TD-1473 [Tablet A]

TD-1473 \[Tablet A\] (1 Tablet = Dose A) proposed commercial tablet formulation

DRUG

TD-1473 [Tablet B]

TD-1473 \[Tablet B\] (2 Tablets = Dose A) current clinical tablet formulation

Trial Locations (2)

68502

Theravance Biopharma Investigational Site, Lincoln

90630

Theravance Biopharma Investigational Site, Cypress

Sponsors
All Listed Sponsors
lead

Theravance Biopharma

INDUSTRY

NCT04587713 - Single Dose Bioavailability and Ethnobridging PK Study in Healthy Subjects | Biotech Hunter | Biotech Hunter